Biologics’ success in other inflammatory conditions such as asthma and atopic dermatitis has spurred much of CRS’s corresponding research.
This review aims to update the growing field of biologics for otolaryngologists who treat CRS and discuss potential future areas of research.
The present study is a literature review of biological therapies studied in CRS was performed. Besides, a detailed review of all biologic therapies targeting inflammatory markers involved in Th1-, Th2-, and Th17-mediated inflammation was performed to identify potential areas for future research. The role of biologic therapies in CRS, endotypes of CRS, current biologic therapies studies in CRS, and the prospective regions for analysis were reviewed.
Sixty-nine unique biologic therapies have been developed for Th1-, Th2-, and Th17-mediated inflammation. Five biologics are currently being investigated for use in patients with CRS with nasal polyposis.
The study concluded that as the biologics’ field continues to expand, remaining up to date on the current literature may help clinicians identify patients who may benefit from biologic therapies. Besides, ongoing research in other inflammatory disorders with shared pathophysiology to CRS may reveal other CRS potential treatments that have not previously been investigated.
Reference: https://journals.sagepub.com/doi/full/10.1177/1945892418787132
